BodyArmor SuperDrink taps Ray Rice as partner, investor
LOS ANGELES — BodyArmor SuperDrink announced that a National Football League star has joined its roster as a partner and investor.
Baltimore Ravens running back Ray Rice will engage in events, promotions, product testing and campaigns both regionally and nationally on behalf of BodyArmor SuperDrink, a line of nutrient enhanced sports drinks. Rice joins gridiron football stars Rob Gronkowski, LeSean McCoy, and Jason Pierre-Paul, as well as rookie baseball phenom Mike Trout.
"Ray is considered elite because he never settles for anything less than super and continues to prove he is one of the top running backs in football," BodyArmor SuperDrink founder and CEO Lance Collins said. "Ray’s game is multifaceted as he excels in all areas when on the field, just as BodyArmor SuperDrink is multifaceted and delivers all of the nutrition and hydration benefits that today’s athlete needs."
Buddy Fruits launches fruit gel pouch
CORAL GABLES, Fla. — Buddy Fruits has launched what it calls the first 100% fruit gel pouch to hit the market.
Buddy Fruits said its new Jiggle Gel pouch further demonstrates the company’s originality in developing products that are portable, healthy and fun to eat. Available in raspberry, strawberry and orange flavors, the vegan, dairy-free and gluten-free fruit gel is only made with fruit and fruit pectin, and touts 70 calories per pouch.
"We’ve had this product in the works for quite some time, and decided that the back-to-school season would be ideal for its release," Buddy Fruits cofunder Fabian Milon said. "Jiggle Gel is advancing traditional gel products, which typically require a bowl and a spoon, all the while making it fun again. Kids will really enjoy this product as it maintains the exciting, jiggly consistency that is often associated with gel snacks. Parents will love it, because it is 100% fruit."
Buddy Fruits can be found in more than 28,000 retailers across the United States.
European Commission approves Watson-Actavis merger
PARSIPPANY, N.J. — European regulators have approved U.S. drug maker Watson’s acquisition of Switzerland-based Actavis, Watson said.
Watson said the European Commission had approved its $5.6 billion purchase of the drug maker, formerly based in Iceland, which Watson announced in April 2012.
Watson expects the transaction to be finished by the end of this year, subject to regulatory approval by the Federal Trade Commission. The acquisition is expected to create the world’s third-largest generic drug maker.
"Approval from the EC represents a significant milestone this week as we work toward the completion of the combination of Watson and Actavis later this year," Watson president and CEO Paul Bisaro said.